Posted by Michael Wonder on 21 Nov 2019
MC2 Therapeutics announces FDA acceptance of its new drug application for Wynzora cream for treatment of plaque psoriasis
20 November 2019 - MC2 Therapeutics today announced that the U.S. FDA has accepted for review the new drug application for Wynzora cream.
MC2 Therapeutics is seeking marketing approval for Wynzora cream for the treatment of plaque psoriasis.
The FDA has set 20 July 2020 as the Prescription Drug User Fee Act action date.
